Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: CT1812 in Mild to Moderate Alzheimer's Disease
NCT03507790Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Oct 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of zervimesine in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc.. Started Oct 2018; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03507790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507790.